Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Marimed (MRMD) Notes Payables (2016 - 2025)

Marimed has reported Notes Payables over the past 12 years, most recently at $2.6 million for Q4 2025.

  • Quarterly Notes Payables fell 50.2% to $2.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.6 million through Dec 2025, down 50.2% year-over-year, with the annual reading at $2.6 million for FY2025, 50.2% down from the prior year.
  • Notes Payables was $2.6 million for Q4 2025 at Marimed, up from $2.3 million in the prior quarter.
  • Over five years, Notes Payables peaked at $5.1 million in Q4 2024 and troughed at $4856.0 in Q1 2021.
  • The 5-year median for Notes Payables is $890000.0 (2023), against an average of $1.7 million.
  • Year-over-year, Notes Payables tumbled 99.98% in 2021 and then soared 2085.5% in 2024.
  • A 5-year view of Notes Payables shows it stood at $1.4 million in 2021, then skyrocketed by 167.66% to $3.8 million in 2022, then tumbled by 80.84% to $723000.0 in 2023, then surged by 608.99% to $5.1 million in 2024, then tumbled by 50.2% to $2.6 million in 2025.
  • Per Business Quant, the three most recent readings for MRMD's Notes Payables are $2.6 million (Q4 2025), $2.3 million (Q3 2025), and $3.4 million (Q2 2025).